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SUPPLEMENTARY NOTES
14. ABSTRACT: One in seven men over the age of 60 will be diagnosed with prostate cancer. Elucidation of early cellular changes that may predict progression to prostate cancer and the identification of factors that may inhibit or reverse these cellular changes would be of great clinical significance. Alteration of the fatty acid synthase (FAS) pathway is an early cellular change that has recently come under investigation. Overexpression of the lipogenic enzyme FAS has been noted in several tumor and pre-cancerous tissue types, including prostatic intraepithelial neoplasia (PIN) and prostate cancer and has been suggested as an independent predictor of disease stage. Approximately 5 men per month over 24 months will be recruited and randomized to receive three months of either fish oil capsules (treatment 1) or olive oil (placebo) capsules (treatment 2). Potential confounding variables are assessed through completion of a comprehensive diet history questionnaire and risk factor questionnaire, assessment of pre and post-treatment PSA and surveillance of medication and supplement use. Compliance will be assessed using pill count and evaluation of RBC fatty acid concentrations. While this study population is limited to men at high risk of disease, the results may be more broadly generalizable to any man considered at risk of prostate cancer due to standard clinical indicators such as a PSA >4μg/ml.
BODY
During FY04 this award has supported study coordination, local and federal human subjects review, subject recruitment and data collection to address our primary aims. We also responded to the Oregon Health & Science University Cancer Institute's (OHSU CI) request for a voluntary audit. Unfortunately, because the audit was drawn out over the course of 9 months, it drastically affected last year's subject recruitment estimate. As a result of the audit, we developed a revised protocol that streamlined our eligibility criteria and added an extra layer of MD oversight prior to randomization. Last year, we failed to include the abstract in Box 14 of our annual DoD report. Please reference the full abstract as our first appendix this year.
HUMAN SUBJECTS REVIEW:
Oversight for our protocol was transferred to USAMRMC HRPO on 1 September 2006; all minor modifications were reported to HRPO at the time of Continuing Review for all three sites. We utilized the HRPO Continuing Review Checklist and wrote corresponding explanation memos for these submissions to HRPO. The OHSU CI audit and its ensuing changes were submitted separately to the DOD as a major modification as well as a part of each site's continuing review. In response to the findings of the OHSU CI audit, we submitted clarifications to the protocol to ensure that we continue to recruit and collect the data in the spirit in which the protocol was conceived and which will answer the scientific questions proposed. The DOD approved modifications for all three sites throughout the year. For log number A-12538.a (PVAMC), the DOD approved the addition of the green tea arm STUDY COORDINATION: Ms. Cox remains the primary staff responsible for patient contact and recruitment procedures as well as on-going contact with collaborating clinicians. However, we welcome Ms. Courtney Maxcy who will soon become the primary study coordinator for the Fish Oil study. Because of our delayed recruitment over the past year, it has been imperative to create new, more pro-active and aggressive recruitment methods with our collaborating clinicians. Ms. Cox and Ms. Maxcy visit one of the two Kaiser clinics every week to maintain relationships with the clinicians, attend the OHSU clinic weekly and are working closely with the PVAMC clinician and his nurse to increase recruitment. All team members are involved in brainstorming new recruitment ideas; Ms. Palma designed a new, more eye-catching advertisement for this study, Ms. Farris also works directly with the PVAMC clinician to kick-start recruitment. In response to a Cancer Institute press release, the study was highlighted in several local papers and on the first page of the local Asian Reporter. There were also multiple radio announcements about the study. Ms. Farris currently retains primary responsibility for human subjects' paper work, continuing review documents and maintains ongoing contact with Johanna Kidwell (CDMRC). Senior research assistant, Ms. Amy Palma, is also available and trained to make recruitment phone calls to potential subjects, conduct visits, record data and complete all paperwork on each participant. All study staff have been trained on how to collect prostate biopsy cores from subjects, which are stored in a -80°C freezer. We submitted these changes to KPNW at the time of annual review, which, as mentioned above, was approved on 8/15/2007. In addition, all research study staff have undergone additional clinical trials training and we have requested and received two voluntary quality assurance audits from the OCTRI Research Support and Services team and the solid tumors group within OHSU CI. Following final approval of the revised protocol and re-opening of recruitment we have worked diligently with the clinicians (as previously described) to enhance recruitment. In the past 7 weeks we have successfully enrolled 5 men into the trial. We are now averaging recruitment of approximately 3 to 4 new subjects per month, and believe that our numerous efforts in revitalizing this trial are now paying off with enhanced recruitment.
PROGRESS TO DATE:
In addition, over the past year, we have continued work to optimize our laboratory procedures for estimating lipid raft and total cholesterol content within the prostate biopsy specimens. Lipid raft fractions were successfully prepared from surgical prostate samples using the methods described by described by Gebreselassie D and Bowen WD (1) and Martens et al (2) using discontinuous sucrose gradients to isolate the Triton X-100 insoluble raft fractions. The total cholesterol in density-gradient fractions will be determined using the Amplex Red Cholesterol Kit (Invitrogen, Molecular Probes, OR, USA). The assay was performed according to manufacturer's instructions. Triplicates of each raft prep fraction (10 µls) were used in the assay and cholesterol standards were made to reflect sucrose/buffer content of each sample. The cholesterol concentration using this method was confirmed with liquid chromatography-mass spectroscopy (LC/MS) (3).
Western Blotting for proteins in lipid raft preparations will be done using a 20 µl sample from each gradient fraction. Blots were probed with antibodies against flotillin 1, caveolin, and human transferring receptor to identify raft and nonraft fractions.
Initial studies were performed with prostate tissue removed during surgical procedures. Using these samples it was possible to remove the majority of the connective tissue and thus obtain a samples that could be homogenized reproducibly in the initial step with a Potter-Elvehjem Teflon-glass homogenizer in 25 mM MES, pH 6.5, with 150 mM NaCl (MBS) and 1% Triton X-100 (v/v). We found that in order to obtain a reproducible raft preparation we needed to start with about 100 mg of prostate tissue. After the intial homogenization and solubilization we were able to obtain a protein concentration of about 20 mg/ml. A representative raft preparation using these conditions is in Fig. 1 . When we attempted to use this protocol with two different needle stick biopsy samples we were not able to obtain detectable raft fractions. As a result, we assessed the possibility of using the needle stick biopsy samples for total cholesterol analysis using the Amplex Red Cholesterol Kit. Biopsy samples were homogenized directly in the assay buffer and a sample removed for protein analysis. We removed different amounts of total protein and found that 10 to 20 µg of total protein provided a reliable and reproducible cholesterol determination. In 2 different biopsy samples we found a range of 5 to 20 ng cholesterol/µg of protein.
As a result, while we will not be able to assess raft fractions from the biopsy samples we will be able to determine the total cholesterol content and thus determine if the statin treatment altered the overall tissue concentrations of cholesterol. KEY RESEARCH ACCOMPLISHMENTS: Immunohistochemistry for fatty acid synthase (FAS) and sterol regulatory element binding protein (SREBP-1) in the biopsy samples will occur in our final year of funding to allow for batching of the work and to ensure that the technicians are unaware of subject status when reviewing the samples. However, methods for quantitation of the cholesterol component of lipid rafts have been fully developed and tested in existing non-study tissue specimens.
REPORTABLE OUTCOMES: None to date
CONCLUSIONS:
The primary outcome of the fourth year was the development of a more streamlined and compliant research protocol and enhancement of our recruitment methods. Through this process our investigative team has gained a great deal of experience in the development and conduct of a clinical trial in prevention. This is proving to be a great asset both to our study team and to the campus as a whole, as this type of translational prevention trial is new and previously there had been no local guidance from clinical trial experts available. We are continuing to recruit from the OHSU and PVAMC urology clinics as well as two separate KPNW urology clinics. Recruitment from these additional sites not only improves our chances of reaching our accrual target, but also allows us to recruit from a more representative group of subjects. To date we have had no serious adverse events, and have only lost one individual post-randomization. 
